Evotec AG (EVTCY) Stock Rating Upgraded by Zacks Investment Research
Evotec AG (NASDAQ:EVTCY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The brokerage presently has a $43.00 price target on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 9.14% from the company’s previous close.
According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “
Several other research analysts have also commented on the company. DZ Bank AG reiterated a “sell” rating on shares of Evotec AG in a research report on Thursday, August 17th. Berenberg Bank lowered Evotec AG from a “buy” rating to a “hold” rating in a research report on Tuesday, June 6th.
Evotec AG (EVTCY) traded up 2.60% during trading on Friday, hitting $39.40. The stock had a trading volume of 1,600 shares. Evotec AG has a 52-week low of $9.79 and a 52-week high of $40.23. The company has a 50-day moving average of $32.69 and a 200 day moving average of $26.12. The firm has a market cap of $2.88 billion and a P/E ratio of 67.70.
Evotec AG (NASDAQ:EVTCY) last issued its earnings results on Thursday, August 10th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by $0.03. The firm had revenue of $58.52 million during the quarter, compared to analysts’ expectations of $50.06 million.
Evotec AG Company Profile
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.